Physician profile
Sandra D Crouse
NPI 1164631255
$4,191.12
in general payments reported to CMS, 2019-2025
39 companies · $215 in 2025
The $215 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,499 · 2020: $851 · 2021: $229 · 2022: $99.37 · 2023: $193 · 2024: $104 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $490.62 | 2019-2020 | |
| Allergan, INC. | $353.44 | 2019-2021 | |
| Abbvie INC. | $314.89 | 2021-2025 | Botox, Ubrelvy |
| Alexion Pharmaceuticals, INC. | $268.15 | 2019-2020 | |
| Biogen, INC. | $247.18 | 2019-2020 | |
| Ucb, INC. | $241.77 | 2019-2023 | Briviact |
| Sunovion Pharmaceuticals INC. | $225.68 | 2019-2020 | |
| Emd Serono, INC. | $212.36 | 2019-2020 | |
| Amgen INC. | $181.87 | 2019-2023 | Aimovig |
| Genentech USA, INC. | $165.27 | 2019-2025 | Ocrevus Zunovo |
| Supernus Pharmaceuticals, INC. | $164.07 | 2019-2020 | |
| Lundbeck LLC | $133.81 | 2019-2024 | Vyepti, Rexulti |
| Genzyme Corporation | $133.64 | 2019-2020 | |
| Greenwich Biosciences, INC. | $128.43 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $126.15 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $89.97 | 2020-2024 | |
| Lilly USA, LLC | $81.44 | 2019-2020 | |
| Csl Behring | $75.56 | 2019 | |
| Eisai INC. | $71.83 | 2019-2024 | |
| Acorda Therapeutics, INC | $50.30 | 2019 | |
| Upsher-Smith Laboratories LLC | $42.94 | 2019-2020 | |
| Livanova USA, INC. | $42.01 | 2019-2022 | |
| Kyowa Kirin, INC. | $41.12 | 2020-2021 | |
| Merz North America, INC. | $33.29 | 2019 | |
| Amneal Pharmaceuticals LLC | $29.89 | 2019 | |
| Mallinckrodt Hospital Products INC. | $22.72 | 2020 | |
| Argenx US, INC. | $21.04 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Aquestive Therapeutics, INC. | $19.81 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.20 | 2020 | |
| Aprecia Pharmaceuticals, LLC | $18.10 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.44 | 2022 | |
| Avanir Pharmaceuticals, INC. | $17.22 | 2020 | |
| Jazz Pharmaceuticals INC. | $16.98 | 2023 | |
| Ge Healthcare | $16.68 | 2019 | |
| Neurelis, INC. | $16.44 | 2020 | |
| Mallinckrodt Enterprises LLC | $15.42 | 2019 | |
| Medtronic USA, INC. | $15.30 | 2020 | |
| Assertio Therapeutics, INC. | $15.08 | 2019 | |
| Promius Pharma LLC | $15.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Crouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.